Financial ForecastThe company's revenue forecast for the coming years has been cut, with a revised lower price objective, suggesting analysts have concerns about future growth prospects.
Market CompetitionRising competition and regulatory pressures in the China market, such as the impact of the Chinese anti-corruption campaign, are likely to challenge the company's sales and market position.
Sales PerformanceMonthly sales of self-developed drugs pamiparib and zanubrutinib have shown a significant decline, indicating a potential decrease in market demand or competitive pressure.